Approval has been granted by the Medicines and Healthcare products Regulatory Agency, or MHRA, for an adapted Pfizer (PFE) and BioNTech (BNTX) COVID-19 vaccine that targets the Omicron XBB 1.5 subvariant, after it was found to meet the UK regulator’s standards of safety, quality and effectiveness, the group announced. The vaccine has been approved for use in individuals from 6 months of age.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- H.C. Wainwright bullish on GeoVax Labs given ‘notable’ 1H23 achievements
- Pfizer, BioNTech report positive CHMP opinion for Omicron XBB.1.5 vaccine
- Drug Companies Mixed as Medicare Plans to Negotiate
- Alnylam intends to appeal ruling on two patents asserted against Moderna
- Biotech Alert: Searches spiking for these stocks today